These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
    Author: Reifart N, Schmidt-Moritz AD, Nadj M, Kaltenbach M, Bussmann WD.
    Journal: Z Kardiol; 1985 Apr; 74(4):205-12. PubMed ID: 3923726.
    Abstract:
    Long-term treatment of congestive heart failure with prazosin is disputed. Only few controlled trials have been reported so far. Our study is the first randomized double-blind placebo controlled trial over several months that also takes haemodynamic measurements into account. 25 patients with congestive heart failure classes III and IV (NYHA) received either prazosin 20 mg/d orally (n = 12) or placebo (n = 13) and were followed up closely. Before treatment, after 6 and after 12 months we performed echocardiography, heart volume (estimated by chest X-ray) and right heart catheterization at rest and during exercise. No significant differences could be noticed during follow-up concerning the following parameters: symptoms (NYHA), left ventricular end-diastolic diameter, shortening fraction, heart volume and systemic vascular resistance. While diuretics could be reduced in 3 patients with placebo an increasing dose was necessary in 6 out of 12 patients of the prazosin group. Long-term treatment of congestive heart failure with prazosin may be valuable only in exceptional cases.
    [Abstract] [Full Text] [Related] [New Search]